公开(公告)号：US20180036271A1

公开(公告)日：2018-02-08

申请号：US15551468

申请日：2016-02-18

Applicant: Aston University

Inventor： Asif AHMED ,  Keqing WANG ,  Shakil AHMAD

IPC: A61K31/198

CPC classification number: A61K31/198 ,  G01N33/689 ,  G01N2800/368 ,  A61K2300/00

Abstract: Described is a method of diagnosis or prognosis of preeclampsia in a pregnant subject, comprising providing a sample from a pregnant subject and measuring the ratio between the amount of (a) one or both of sFlt-1 and PlGF, and (b) one or both of a breakdown product of heme and a breakdown product of arginine, in the sample. Also described are assay kits and a computer adapted for use in the method. Also described is a method of treating preeclampsia, comprising administering a pharmaceutically effective amount of L-arginine and/or citrulline and an inhibitor of arginase or pharmaceutically acceptable salts thereof. Also described is a method of treating cancer, comprising treating a subject with a therapeutically effective amount of an anti-VEGF compound, L-arginine and an arginase inhibitor.

公开(公告)号：US20200038354A1

公开(公告)日：2020-02-06

申请号：US16516597

申请日：2019-07-19

Applicant: Aston University

Inventor： Asif AHMED ,  Keqing WANG ,  Shakil AHMAD

IPC: A61K31/198 ,  G01N33/68

Abstract: The invention provides a method of diagnosis or prognosis of preeclampsia in a pregnant subject, comprising providing a sample from a pregnant subject and measuring the ratio between the amount of (a) one or both of sFlt-1 and PlGF, and (b) one or both of a breakdown product of heme and a breakdown product of arginine, in the sample. Also described are assay kits and a computer adapted for use in the method. Also described is a method of treating preeclampsia, comprising administering a pharmaceutically effective amount of L-arginine and/or citrulline and an inhibitor of arginase or pharmaceutically acceptable salts thereof. Also described is a method of treating cancer, comprising treating a subject with a therapeutically effective amount of an anti-VEGF compound, L-arginine and an arginase inhibitor.

公开(公告)号：US20200289540A1

公开(公告)日：2020-09-17

申请号：US16847499

申请日：2020-04-13

Applicant: ASTON UNIVERSITY

Inventor： Meng CAI ,  Keqinq WANG ,  Asif AHMED

IPC: A61K31/713 ,  C12Q1/6883 ,  C12N15/11 ,  G01N33/50

Abstract: The invention provides a method of treating preeclampsia, fetal growth restriction (FGR or IUGR), obesity in pregnancy, post-partum cardiomyopathy (heart failure in mothers), cancer and diabetic retinopathy, cardiomyopathy, myocardial infarction, wet microdegeneration and other disorders where angiogenesis is aberrant either diminished or exacerbated, comprising modulating the activity of micro RNA (miRNA). Also provided are an MiRNA modulator or a combination thereof or functional fragments or homologues thereof for use in the treatment of preeclampsia, fetal growth restriction, obesity in pregnancy, cancer, and diabetic retinopathy, cardiomyocyte infarction, wet microdegeneration as well as other disorder where angiogenesis is aberrant either diminished or exacerbated. Methods of modulating angiogenesis and pharmaceutical compositions using miR-122, miR-374b or inhibitors of miR-152 or miR195 are also provided together with methods of diagnosis using the miRNAs.

公开(公告)号：US20190328756A1

公开(公告)日：2019-10-31

申请号：US16229173

申请日：2018-12-21

Applicant: Aston University

Inventor： Asif AHMED ,  Keqing WANG

IPC: A61K31/675 ,  A61K31/095

Abstract: The application describes Hydrogen Sulphide (H2S), or a (H2S) generating compound or compound capable of stimulating H2S production in a pregnant subject, for use in the treatment of pre-eclampsia (PE) or fetal growth restriction.

公开(公告)号：US20160129022A1

公开(公告)日：2016-05-12

申请号：US14771285

申请日：2014-03-03

Applicant: ASTON UNIVERSITY

Inventor： Asif AHMED ,  Keqing WANG

IPC: A61K31/675

CPC classification number: A61K31/675 ,  A61K31/095

Abstract: The application describes Hydrogen Sulphide (H2S), or a (H2S) generating compound or compound capable of stimulating H2S production in a pregnant subject, for use in the treatment of pre-eclampsia (PE) or fetal growth restriction.

Abstract translation: 该申请描述了用于治疗先兆子痫（PE）或胎儿生长限制的硫化氢（H2S）或（H2S）产生化合物或能够刺激怀孕受试者中的H2S产生的化合物。

公开(公告)号：US20220000821A1

公开(公告)日：2022-01-06

申请号：US17348942

申请日：2021-06-16

Applicant: Aston University

Inventor： Asif AHMED ,  Keqing WANG ,  Shakil AHMAD

IPC: A61K31/198 ,  G01N33/68

Abstract: Described is a method of diagnosis or prognosis of preeclampsia in a pregnant subject, comprising providing a sample from a pregnant subject and measuring the ratio between the amount of (a) one or both of sFlt-1 and PlGF, and (b) one or both of a breakdown product of heme and a breakdown product of arginine, in the sample. Also described are assay kits and a computer adapted for use in the method. Also described is a method of treating preeclampsia, comprising administering a pharmaceutically effective amount of L-arginine and/or citrulline and an inhibitor of arginase or pharmaceutically acceptable salts thereof. Also described is a method of treating cancer, comprising treating a subject with a therapeutically effective amount of an anti-VEGF compound, L-arginine and an arginase inhibitor.

公开(公告)号：US20180050060A1

公开(公告)日：2018-02-22

申请号：US15559815

申请日：2016-03-16

Applicant: ASTON UNIVERSITY

Inventor： Meng CAI ,  Keqinq WANG ,  Asif AHMED

IPC: A61K31/713 ,  C12N15/11 ,  C12Q1/68 ,  G01N33/50

CPC classification number: A61K31/713 ,  C12N15/111 ,  C12N2310/113 ,  C12N2310/141 ,  C12N2320/30 ,  C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/178 ,  G01N33/50

Abstract: The invention provides a method of treating preeclampsia, fetal growth restriction (FGR or IUGR), obesity in pregnancy, post-partum cardiomyopathy (heart failure in mothers), cancer and diabetic retinopathy, cardiomyopathy, myocardial infarction, wet microdegeneration and other disorders where angiogenesis is aberrant either diminished or exacerbated, comprising modulating the activity of micro RNA (miRNA). Also provided are an MiRNA modulator or a combination thereof or functional fragments or homologues thereof for use in the treatment of preeclampsia, fetal growth restriction, obesity in pregnancy, cancer, and diabetic retinopathy, cardiomyocyte infarction, wet microdegeneration as well as other disorder where angiogenesis is aberrant either diminished or exacerbated. Methods of modulating angiogenesis and pharmaceutical compositions using miR-122, miR-374b or inhibitors of miR-152 or miR195 are also provided together with methods of diagnosis using the miRNAs.